Repatha (Evolocumab) FAERS Safety Signals: A Women's Guide to FDA Adverse Event Data

What Is Repatha and Why Does It Matter More for Women Than You Might Think?

Repatha (evolocumab) is a fully human monoclonal antibody that targets proprotein convertase subtilisin/kexin type 9, commonly called PCSK9. By blocking PCSK9, the drug keeps LDL receptors recycling to the liver cell surface, which means your bloodstream clears LDL particles more efficiently. The result is a dramatic drop in LDL cholesterol that statins alone rarely achieve.

Cardiovascular disease is the leading cause of death in American women, claiming roughly 1 in 5 female lives each year. Yet women have historically been enrolled in cardiovascular trials at lower rates than men, so the sex-specific data we need to make fully informed decisions is thinner than it should be. That matters when you are deciding whether to add a biologic injectable to your regimen, and it matters even more when you are perimenopausal, managing PCOS, or considering pregnancy.

How PCSK9 Physiology Differs in Women

PCSK9 levels are not static across your reproductive life. Estrogen suppresses hepatic PCSK9 expression, which is one reason premenopausal women tend to have lower LDL than age-matched men. After menopause, estrogen withdrawal allows PCSK9 activity to rise, and LDL cholesterol climbs an average of 10-14 mg/dL in the years surrounding the final menstrual period. This hormonal shift is a major reason postmenopausal women often develop dyslipidemia that was absent during their reproductive years.

Women with PCOS present a separate pattern. Insulin resistance in PCOS upregulates PCSK9, contributing to the dyslipidemia (high triglycerides, low HDL, small dense LDL) that characterizes the condition even in the absence of obesity. Statin-intolerant women with PCOS and markedly elevated LDL are therefore a real clinical population for whom evolocumab is sometimes considered.

The FOURIER Trial: What It Told Us About Women

The key FOURIER trial enrolled 27,564 patients with established atherosclerotic cardiovascular disease on optimized statin therapy. Evolocumab reduced LDL from a median of 92 mg/dL to 30 mg/dL, a 59% reduction, and cut the composite cardiovascular endpoint (MI, stroke, cardiovascular death, hospitalization for unstable angina, or coronary revascularization) by 15% over a median 2.2 years. That is the headline.

What the headlines rarely say: only about 25% of FOURIER participants were women. Sex-disaggregated analyses suggested the relative risk reduction was directionally similar in women and men, but the trial was not powered to detect sex differences with statistical confidence. Women in the trial were slightly older at enrollment than male participants and had a higher burden of diabetes. The absolute risk reduction in women was numerically smaller, consistent with their lower baseline event rates, not evidence that the drug works less well.

FDA Approval History and the Evolocumab Label

Approval Timeline

The FDA approved evolocumab on August 27, 2015, under the brand name Repatha. The initial indications were adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), or primary hyperlipidemia requiring additional LDL lowering beyond diet and maximally tolerated statin therapy. A cardiovascular-risk reduction indication was added in December 2017, following the FOURIER results.

What the Current Prescribing Label States

The current Repatha prescribing information carries several label-specific points that women should know:

• Contraindications: Known hypersensitivity to evolocumab or any excipient.
• Warnings: Serious allergic reactions (angioedema, rash) have been reported. Patients should be instructed to stop the drug and seek care immediately if systemic hypersensitivity occurs.
• Adverse reactions: In pooled clinical trials, injection-site reactions occurred in 3.2% of evolocumab-treated patients vs. 3.0% with placebo. Nasopharyngitis, upper respiratory infection, influenza, back pain, and injection-site reactions were the most commonly reported events.
• Drug interactions: No clinically meaningful pharmacokinetic interactions have been identified, though the label notes that statin co-administration (the most common real-world scenario) does not alter evolocumab exposure.

The label is explicit that neurocognitive events were monitored given theoretical concerns, but the EBBINGHAUS cognitive sub-study of FOURIER found no difference in cognitive function between evolocumab and placebo over 19 months of follow-up.

FAERS Safety Signals: Reading the Post-Market Data

What FAERS Is and What It Is Not

The FDA Adverse Event Reporting System (FAERS) is a pharmacovigilance database that collects voluntary and mandatory reports of adverse events and medication errors from patients, healthcare providers, and manufacturers. As of mid-2024, the FAERS public dashboard lists thousands of reports for evolocumab. Understanding these data requires care: FAERS reports establish signals, not causation. Report counts reflect reporting rates, not incidence rates in the treated population. Women tend to report adverse drug events at higher rates than men across most drug classes, so female-dominant signals in FAERS can partly reflect reporting behavior, not exclusively biology.

Top Signals for Evolocumab in FAERS

Querying FAERS data for evolocumab (search term: "REPATHA" and "EVOLOCUMAB") yields several recurring signal categories:

Musculoskeletal events. Myalgia, muscle spasms, and arthralgia appear consistently. This is clinically expected: most patients on evolocumab are also on statins, and statin-associated muscle symptoms (SAMS) are more common in women, older patients, and those with low body weight or hypothyroidism. Disentangling evolocumab-attributable myalgia from background statin-related SAMS is genuinely difficult in FAERS, because the drug is almost never used as monotherapy in real-world practice.

Injection-site reactions. Erythema, pain, and bruising at the injection site are the most consistently reported events and align with the phase III data. Women with thinner subcutaneous tissue layers (common in lean postmenopausal women) may experience more pronounced local reactions.

Flu-like symptoms. Nasopharyngitis and upper respiratory tract infections are the most common events in both trial and post-market data, though these are also highly common background events in any adult population.

Neurocognitive complaints. Memory impairment and confusion appear in FAERS for evolocumab at low frequencies. The EBBINGHAUS study specifically addressed this signal and found no signal of harm on spatial working memory, executive function, or psychomotor speed after approximately 19 months. The FDA has not required a neurocognitive warning for PCSK9 inhibitors, unlike the class-wide warning that was briefly considered before EBBINGHAUS results were available.

Allergic/hypersensitivity reactions. Rash, urticaria, and rare angioedema cases appear in FAERS. The label notes these and advises discontinuation if severe hypersensitivity occurs. Women account for a disproportionate share of drug-induced hypersensitivity reactions broadly, though evolocumab-specific sex disaggregation in FAERS is not publicly reported in a format that allows precise rate comparison.

FDA Sentinel and Signal Assessment

Beyond FAERS, the FDA uses the Sentinel System, a distributed active surveillance network covering over 300 million patient-lives, to evaluate post-market signals. No public FDA drug-safety communication has been issued for evolocumab as of the date of this article, which means the Sentinel system has not confirmed a safety signal requiring label action beyond what was already known from trials. That is meaningful reassurance, though it does not eliminate the importance of monitoring for individual patients.

Pregnancy, Lactation, and Contraception: What the Evidence Actually Shows

Cardiovascular risk does not pause during the reproductive years. Women with familial hypercholesterolemia, PCOS-related dyslipidemia, or prior atherosclerotic events may face a question their clinicians rarely answer with specificity: what happens if I need evolocumab and I am pregnant or planning to conceive?

Pregnancy: No Adequate Human Data

Repatha is classified under the FDA's Pregnancy and Lactation Labeling Rule (PLLR) framework, which replaced the old letter-category system. The label states: "There are no available data on REPATHA use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes."

Animal data are relevant here. In cynomolgus monkeys, evolocumab administered at doses 12-fold the human exposure did not produce fetal harm. However, IgG monoclonal antibodies cross the placenta via the FcRn receptor, particularly in the second and third trimesters, meaning fetal exposure likely occurs in human pregnancies even though maternal LDL-lowering during pregnancy is not an established clinical benefit. The placental transfer concern is real: blocking PCSK9 in the fetus could theoretically interfere with cholesterol metabolism during critical developmental windows, given that cholesterol is essential for fetal brain myelination and steroidogenesis.

Bottom line for pregnancy: Evolocumab should be avoided during pregnancy unless the maternal cardiovascular risk is so severe that the potential benefit clearly outweighs an unknown fetal risk. If you discover you are pregnant while taking Repatha, contact your clinician immediately. Do not stop a statin or evolocumab without clinical guidance if you have a serious cardiac condition.

Women with heterozygous or homozygous FH face a particularly difficult dilemma during pregnancy. LDL rises approximately 25-50% during normal pregnancy due to physiologic changes in lipoprotein metabolism. For a woman with HoFH whose pre-pregnancy LDL may already exceed 400 mg/dL, that rise carries real maternal cardiovascular risk. LDL apheresis is currently the preferred intervention in such cases in the US and UK, as it removes LDL physically without fetal drug exposure.

Lactation: Unknown Transfer

The label states that it is not known whether evolocumab is present in human milk. IgG antibodies are present in colostrum and breast milk in small amounts, but the large molecular weight of evolocumab (144 kDa) makes significant oral absorption by a nursing infant biologically unlikely, since neonatal gut proteases would degrade most ingested IgG. The theoretical risk has not been formally excluded with pharmacokinetic studies in lactating women, which represents an evidence gap. The standard clinical recommendation is to weigh the benefit of breastfeeding against the maternal need for the drug, and to discuss timing of doses relative to feeding sessions.

Contraception Considerations

Evolocumab is not a known teratogen in the same category as statins, which carry a contraindication in pregnancy and require reliable contraception during use. There is no FDA-mandated contraception requirement for evolocumab. Still, given the absence of human pregnancy safety data and the physiologic plausibility of placental transfer, any woman of reproductive age starting evolocumab should have a proactive contraception conversation with her prescriber, particularly if she is on high-dose or long-term therapy.

Who Is This Drug Right For? A Life-Stage View

Reproductive Years (Ages ~18-45)

Women in their reproductive years are the least likely to need evolocumab for atherosclerotic cardiovascular disease, but the most likely to need it for familial hypercholesterolemia. HeFH affects approximately 1 in 250 people and is often diagnosed in young women who cannot tolerate statins or whose LDL remains uncontrolled despite maximal statin therapy. In this group, evolocumab offers a meaningful alternative, with the pregnancy and lactation caveats above front and center in the discussion.

Women with PCOS and markedly elevated LDL who are statin-intolerant also fall into this category. PCSK9 inhibition in PCOS-related dyslipidemia has not been studied in dedicated trials, which is a gap that needs naming.

Perimenopause (Approximately Ages 45-55)

The menopausal transition is when LDL often climbs fastest and when cardiovascular risk begins to accelerate. Estrogen decline allows PCSK9 to be more active, driving LDL higher. A perimenopausal woman whose LDL was well-controlled on a moderate-intensity statin may find that same statin becomes inadequate by her mid-50s. Adding evolocumab in this group is well-supported by the FOURIER age-stratified analyses, which showed consistent benefit across age groups, though the trial enrolled relatively few women under 55.

Perimenopausal women are also at higher risk for statin-associated muscle symptoms, possibly because declining estrogen reduces skeletal muscle resilience. If SAMS are driving a switch to evolocumab as a statin-sparing strategy, the GAUSS-3 trial demonstrated that evolocumab reduced LDL by 52.8% in statin-intolerant patients vs. Ezetimibe, with significantly fewer muscle events.

Postmenopause

Postmenopausal women with established atherosclerotic cardiovascular disease are the population best represented in FOURIER and represent the clearest indication. The drug's injection schedule (every 2 weeks or monthly) fits a stable chronic-disease regimen. Bone health, which is a separate concern in postmenopausal women, does not appear to be adversely affected by PCSK9 inhibition. Some preclinical data suggest PCSK9 may play a role in osteoblast function, but no clinical trial has documented evolocumab-associated bone loss.

Who This Is Not Right For

Evolocumab is not appropriate for women whose LDL is only modestly elevated and who have not yet tried dietary intervention, moderate-intensity statin therapy, and ezetimibe. Cost and injection burden are real barriers. The list price of Repatha exceeds $600 per month without insurance, and prior authorization requirements are common. Women with a history of serious hypersensitivity to any monoclonal antibody should avoid it. Pregnancy, as discussed above, warrants avoidance unless the clinical situation is extreme.

Evidence Gaps Specific to Women

The honest answer about evolocumab and women is that we are working with incomplete data in several areas. Women represented only about 25% of FOURIER enrollees. Sex-disaggregated FAERS analyses are not publicly reported by FDA in a standardized format. No trial has enrolled pregnant women, which is ethically understandable but clinically frustrating for women with FH who need actionable guidance. PCSK9 inhibition in PCOS-specific dyslipidemia has not been studied as a primary endpoint in any published RCT.

ACOG does not currently have a practice bulletin specifically addressing PCSK9 inhibitors in pregnancy or the peripartum period, though cardiovascular disease in pregnancy guidance touches on lipid management in the context of FH. The Menopause Society's 2023 position statement on menopause and cardiovascular disease discusses dyslipidemia management broadly but does not provide evolocumab-specific recommendations for the perimenopause transition.

These gaps are worth naming to your prescriber. Asking "what data exists specifically in women my age with my health history" is a reasonable and clinically sound question that good prescribers will welcome.

Practical Safety Monitoring for Women on Repatha

If you are prescribed evolocumab, the following monitoring framework applies specifically to female physiology:

• Lipid panel: At baseline, 4-12 weeks after starting or changing dose, then annually once stable. Women's LDL targets for high-risk or very-high-risk cardiovascular disease are the same as men's per ACC/AHA 2019 guidelines: LDL <70 mg/dL for high risk, <55 mg/dL for very high risk.
• Thyroid function: Hypothyroidism, which affects women at roughly 5 times the rate of men, worsens dyslipidemia and increases SAMS risk. A baseline TSH and periodic re-check are warranted in any woman on lipid-lowering therapy, including evolocumab.
• Muscle symptoms: Report myalgia, weakness, or dark urine immediately. A CK level at baseline and whenever symptoms arise is reasonable clinical practice.
• Pregnancy testing: Any woman of reproductive potential who develops nausea, breast tenderness, or missed periods while on evolocumab should take a pregnancy test promptly given the absence of safety data.
• Injection-site care: Rotate injection sites (abdomen, thigh, upper arm). Allow the autoinjector to reach room temperature for at least 30 minutes before use to reduce local discomfort, a practical tip with outsized impact on adherence.

"Women with familial hypercholesterolemia face a compounded disadvantage: they are more likely to be undertreated with high-intensity statins than men with the same LDL levels, and they face a near-complete evidence gap during pregnancy. PCSK9 inhibitors may fill a real clinical need, but we must be honest that the safety data in pregnancy is essentially animal-level, not human-level." Dr. Elena Vasquez, MD, WomanRx Editorial Board.